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Thyroid hormone treatment in brain-dead organ donors has been extensively studied and
applied in the clinical setting. However, its clinical applicability remains controversial due to
a varying degree of success and a lack of mechanistic understanding about the therapeutic
effects of 3,3’,5-Triiodo-L-thyronine (T3). T3 pre-conditioning leads to anti-apoptotic and pro-
mitotic effects in liver tissue following ischemia/reperfusion injury. Therefore, we aimed to
study the effects of T3 pre-conditioning in the liver of brain-dead rats.
Methods
Brain death (BD) was induced in mechanically ventilated rats by inflation of a Fogarty cathe-
ter in the epidural space. T3 (0.1 mg/kg) or vehicle was administered intraperitoneally 2 h
prior to BD induction. After 4 h of BD, serum and liver tissue were collected. RT-qPCR, rou-
tine biochemistry, and immunohistochemistry were performed.
Results
Brain-dead animals treated with T3 had lower plasma levels of AST and ALT, reduced Bax
gene expression, and less hepatic cleaved Caspase-3 activation compared to brain-dead
animals treated with vehicle. Interestingly, no differences in the expression of inflammatory
genes (IL-6, MCP-1, IL-1β) or the presence of pro-mitotic markers (Cyclin-D and Ki-67)
were found in brain-dead animals treated with T3 compared to vehicle-treated animals.
Conclusion
T3 pre-conditioning leads to beneficial effects in the liver of brain-dead rats as seen by lower
cellular injury and reduced apoptosis, and supports the suggested role of T3 hormone ther-
apy in the management of brain-dead donors.
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Introduction
Organ transplantation is the treatment of choice for patients with end stage liver disease.
However, shortage of organs is one of the most important challenges in the transplantation
field [1]. The majority of organs available for transplantation stems from brain-dead donors
[2]. Grafts from brain-dead donors, however, have more frequent delayed graft function and
higher rejection rates compared to living donors [3–5]. Therefore, research has focused on
understanding and treating the pathophysiological processes during brain death (BD) to
optimize transplantation outcomes. Until now, the available evidence suggests that the nega-
tive effects of BD in organ donation can be explained by hemodynamic instability [6–9],
global hormonal failure [10–12], and a systemic inflammatory response led by the innate
immune system [13–16].
During the onset of BD, the intracranial pressure (ICP) increases, leading to progressive
ischemia of the cerebrum, brain stem, and spinal cord. This increase in ICP triggers a sympa-
thetic response causing systemic hypertension, also called the Cushing reflex [17]. When sys-
temic hypertension fails to maintain cerebral perfusion, ischemia of the brain stem results in
failure of the hypothalamus and pituitary. Thereby, cessation of the hypothalamic-pituitary
axis negatively affects systemic hormone regulation, seen by changes in levels of vasopressin,
cortisol, and adrenocorticotropic and thyroid hormones [18]. Following the onset of BD,
plasma levels of free 3,3’,5-Triiodo-L-thyronine (T3) fall to 50% of baseline levels within 1 h
after BD and become undetectable after 9 h, whereas levels of thyroid stimulating hormone,
free thyroxine, reverse T3, and cortisol are variable [11, 19].
In the clinical setting, thyroid hormone treatment in brain-dead donors has been extensively
studied and applied [11, 19–21]. However, there remains controversy about the effectiveness of
thyroid therapy due to varying degrees of success. Moreover, the mechanisms behind the thera-
peutic effects of thyroid hormones are only beginning to be understood [22]. Even though
reports have shown beneficial effects of thyroid hormone replacement on the hemodynamic
status of the donor, no conclusive evidence has been published [23–26]. Interestingly, recent
data from the Organ Procurement and Transplant Network database show an increase in the
use of hormonal replacement therapy including thyroid infusion, which is accompanied by
increased organ availability [27, 28]. Moreover, early treatment of potential donors with
levothyroxine before the declaration of BD is associated with a significant increase in organs
donated per donor and reduced vasoactive support [29, 30]. Thus, improving and expanding
the treatment of potential donors can lead to an increase in the number of transplantable
organs. These beneficial effects of earlier donor treatment could be explained by protective pre-
conditioning effects of thyroid hormones, as seen in models of ischemia/reperfusion (I/R)-
injury [31, 32] and regeneration in the liver [33, 34]. In these models, T3 pre-treatment reduces
hepatic injury and apoptosis, and increases liver cell regeneration. Moreover, T3 induces hepa-
tocyte proliferation in rat models in vitro and in vivo, through reduction of apoptosis and stim-
ulation of liver cell regeneration.
Given the shift towards earlier treatment of potential donors, the current discussion in the
literature, and lack of consensus regarding the effectiveness of thyroid therapy, we aimed to
look at the effects of thyroid hormone pre-conditioning in the liver using a well-established BD
model in rats. We hypothesized T3 pre-conditioning could improve liver quality by reducing
apoptosis and increasing cellular growth rate. A deeper understanding about the therapeutic
effects of T3 therapy is required to improve treatment of brain-dead donors and, ultimately,
increase organ quality and lower rejection rates.
Anti-Apoptotic Effects of T3 in the Liver of Brain-Dead Rats
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Materials and Methods
Animals and treatment
Male, adult, Fisher F344 rats (250–300 g) were used. All animals received care in compliance
with the guidelines of the Institutional Animal Care and Use Committee—Rijksuniversiteit
Groningen (IACUC-RUG) according to Experiments on Animals Act (1996) issued by the
Ministry of Public Health, Welfare and Sports of the Netherlands. The IACUC-RUG
approved this study and all animal care actions. In order to ameliorate suffering, animals
were anesthetized using isoflurane during the entire surgical procedure. BD was induced
under anesthesia, as previously described [35]. In brief, the procedure was as follows: animals
were anesthetized using isoflurane with 100% O2. Animals were intubated via a tracheostomy
and ventilated as follows: tidal volume of 2.5 ml per stroke, positive end-expiratory pressure
of 2 cm of H20, and initial respiratory rate (RR) of 80 cycles per min. RR was corrected based
on end tidal CO2 levels throughout the experiment. Cannulas were inserted in the femoral
artery and vein for continuous mean arterial pressure (MAP) monitoring and volume
replacement. Through a frontolateral hole in the skull, a no. 4 Fogarty catheter (Edwards
Lifesciences Co, Irvine, USA) was placed in the epidural space and slowly inflated (0.16 ml/
min) with saline using a syringe pump (Terufusion, Termo Co, Tokyo, Japan). Inflation of
the balloon was terminated once a steep rise in the MAP was noted, reflecting the autonomic
storm at the beginning of BD. BD was confirmed by the absence of corneal reflexes and a pos-
itive apnea test. Following confirmation of BD, ventilation was continued and anesthesia ter-
minated. MAP was maintained above 80 mmHg. If necessary, colloid infusion with
polyhydroxyethyl starch (HAES) 10% (Fresenius Kabi AG, Bad Homburg, Germany) was
started (at a maximum rate of 1 ml/h) to maintain a normotensive MAP. Unresponsiveness
to HAES administration indicated the start of an intravenous noradrenaline (NA) drip (1
mg/ml). A homeothermic blanket control system was used throughout the experiment. Four
hours after the confirmation of BD, blood and urine were collected, after which all abdominal
organs were flushed with cold saline. After the flush-out, organs were harvested and tissue
samples snap-frozen in liquid nitrogen and stored at -80°C or fixated in 4% paraformalde-
hyde. Plasma samples and urine were also snap-frozen.
Rats were randomly assigned to each group (n = 7 per group). Sham-operated rats served as
controls and were ventilated for 0.5 h under anesthesia. T3 (Sigma-Aldrich, cat. nr. T6397) or
an equivalent volume of hormone vehicle (0.1 N NaOH, pH = 7.4) was administered intraperi-
toneally 2 h before the BD period. T3 dosage (0.1 mg/kg) was chosen based on previous work
[31]. This experiment proved the pre-conditioning effects of T3 in a model of hepatic I/R-
injury.
The following experimental groups were studied:
• Sham-operated animals pre-treated with vehicle.
• Sham-operated animals pre-treated with T3.
• Brain-dead animals pre-treated with vehicle.
• Brain-dead animals pre-treated with T3.
0.1 Plasma determinations
Plasma levels of alanine transaminase (ALT) and aspartate transaminase (AST) were deter-
mined at the clinical chemistry lab of the University Medical Center Groningen according to
standard procedures.
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0.2 RNA isolation and cDNA synthesis
Total RNA was isolated from whole liver sections using TRIzol (Life Technologies, Gaithers-
burg, USA). Samples were verified for absence of genomic DNA contamination by performing
RT-PCR reactions in which the addition of reverse transcriptase was omitted, using Glyceral-
dehyde 3-phosphate dehydrogenase primers. For cDNA synthesis, 1 μl T11VN Oligo-dT (0,5
μg/μl) and 1 μg mRNA were incubated for 10 min at 70°C and cooled directly after that. cDNA
was synthesized by adding a mixture containing 0.5 μl RnaseOUT Ribonuclease inhibitor
(Invitrogen, Carlsbad, USA), 0.5 μl RNase water (Promega), 4 μl 5x first strand buffer (Invitro-
gen), 2 μl DTT (Invitrogen), 1 μl dNTP’s, and 1 μl M-MLV reverse transcriptase (Invitrogen,
200U). The mixture was kept at 37°C for 50 min. Next, reverse transcriptase was inactivated by
incubating the mixture for 15 min at 70°C. Samples were stored at -20°C.
0.3 Real-Time PCR
Fragments of several genes involved in inflammation (interleukin (IL)-6, IL-1β, and monocyte
chemotactic protein 1 (MCP-1)), apoptosis (bcl-2-associated X (Bax) and B-cell lymphoma 2
(Bcl-2)), mitosis (Cyclin-D), and oxidative stress (signal transducer and activator of transcrip-
tion 3 (STAT3) and nuclear transcription factor erythroid 2-related factor 2 (Nrf2)) were ampli-
fied with the primer sets outlined in Table 1. Pooled cDNA obtained from brain-dead rats was
used as internal reference. Gene expression was normalized with the mean β-actin mRNA con-
tent. Real-Time PCR was carried out in reaction volumes of 15 μl containing 10 μl of SYBR
Green mastermix (Applied biosystems, Foster City, USA), 0.4 μl of each primer (50 μM), 4.2 μl
of nuclease free water, and 10 ng of cDNA. All samples were analyzed in triplicate. Thermal
cycling was performed on the Taqman Applied Biosystems 7900HT Real-Time PCR System
with a hot start for 2 min at 50°C, followed by 10 min at 95°C. The second stage started with 15
s at 95°C (denaturation step) and 60 s at 60°C (annealing step and DNA synthesis). The latter
stage was repeated 40 times. Stage 3 was included to detect formation of primer dimers (melting
curve) and began with 15 s at 95°C, followed by 60 s at 60°C and 15 s at 95°C. Primers were
designed with Primer Express software (Applied Biosystems) and primer efficiencies were tested
by a standard curve for the primer pair, resulting from amplification of a serial dilution of
cDNA samples (10 ng, 5 ng, 2.5 ng, 1.25 ng, and 0.625 ng) obtained from brain-dead rats. PCR
efficiency was 1.8<  < 2.0. Real-time PCR products were checked for product specificity on a
1.5% agarose gel. Results were expressed as 2−44CT (CT: Threshold Cycle).
0.4 Immunohistochemistry and histopathological evaluation
Immunohistochemistry was performed on 3 μm sections of paraffin-embedded liver samples
to detect cleaved caspase 3 (cC3), Ki-67, and heme oxygenase 1 (HO-1) positive cells. The
Table 1. Primer sequences used for Real-Time PCR.
Gene Primers Amplicon size (bp)
IL-1β 5’- CAGCAATGGTCGGGACATAGTT-3’ 5’-GCATTAGGAATAGTGCAGCCATCT-3’ 75
IL-6 5’-CCAACTTCCAATGCTCTCCTAATG-3’ 5’-TTCAAGTGCTTTCAAGAGTTGGAT-3’ 89
MCP-1 5’-CTTTGAATGTGAACTTGACCCATAA-3’ 5’-ACAGAAGTGCTTGAGGTGGTTGT-3’ 78
Bax 5’-GCGTGGTTGCCCTCTTCTAC-3’ 5’-TGATCAGCTCGGGCACTTTAGT-3’ 74
Bcl-2 5’-CTGGGATGCCTTTGTGGAA-3’ 5’-TCAGAGACAGCCAGGAGAAATCA-3’ 70
Cyclin D 5’-CAGCATTGTGCTAATGTAAAGCCAG-3’ 5’-TGGGACGCCTCAGCTAAGCT-3’ 103
STAT3 5’-TTCGAGGCAGTCATTGCTCTC-3’ 5’-ACGCCTTGCCTTCCTAAATACC-3’ 97
Nrf2 5’-CAACGAAGCTCAGCTTGCATTA-3’ 5’-TCCTACAGTTCTGAGCGGCAAC-3’ 76
doi:10.1371/journal.pone.0138749.t001
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active form (cleaved) of caspase 3 was assessed to study apoptosis. Ki-67 is a cellular marker
used to study proliferation [36], whereas HO-1 is an oxidative stress response marker [37]. Sec-
tions were deparaffinized in a sequence of xylene, alcohol, and water, and subjected to heat-
induced antigen retrieval by microwave heating in 1 mM EDTA buffer (pH = 8.0, for cC3), 10
mM citrate buffer (pH = 6.0, for Ki-67), or overnight incubation in 0.1 M Tris/HCl buffer at
80°C (pH = 9.0, for HO-1). Next, sections were stained with cC3 pAb (Cell Signaling, cat. nr.
9661, 100 x diluted in 1% BSA/PBS), Ki-67 pAb (Abcam, cat. nr. 15580, 500 x diluted in 1%
BSA/PBS + 1% Triton) or HO-1 mAb (Stressgen, cat. nr. ADI-OSA-111F, 250 x diluted in 1%
BSA/PBS) using an indirect immunoperoxidase technique. Endogenous peroxidase was
blocked using H2O2 0.3% in phosphate-buffered saline for 30 min. After thorough washing,
sections were incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG as a sec-
ondary antibody for 30 min (Dako, Glostrup, Denmark, cat. nr. P0448), followed by rabbit
anti-goat IgG as a tertiary antibody for 30 min (Dako, Glostrup, Denmark, cat. nr. P0449). The
reaction was developed using DAB as chromogen and H2O2 as substrate. Sections were coun-
terstained using Mayer hematoxylin solution (Merck, Darmstadt, Germany). Negative anti-
body controls were performed. Localization of immunohistochemical staining was assessed by
light microscopy. For each tissue section, positive cells per field were counted by two blinded
researchers in 10 microscopic fields of the tissue at 20 x magnification. Results were presented
as number of positive cells per field. Additional HO-1 intensity quantification was performed
using Aperio Image Scope (Leica Biosystems, Nussloch, Germany), with algorithm positive
pixel count v9 to perform the analysis. Data are presented as total intensity per area (mm2).
The extent of hepatic injury was determined in 3 μm sections of hematoxylin-eosin (HE)
stained, paraffin-embedded slides, which were blindly scored by a pathologist. Slides were
scored for conservation of cytoarchitecture and lobule organization, hepatocyte appearance,
localization of portal and central veins, and amount of necrosis.
Statistical analysis
Due to the two-factorial design of the experiment, the two-way ANOVA test was used to ana-
lyze the results (SPSS Statistics 20, IBM Software, NY, USA). Data were checked for a normal
distribution and equality of variances of the dependent variable across groups using Levene’s
test of equality of error variances (indicated by p> 0.05). Data transformations were applied if
these assumptions were not met, after which data were normally distributed and variances of
the dependent variable equal across groups. This allowed us to use the two-way ANOVA test
despite small group sizes. For AST and the Bax/Bcl-2 ratio, data did not meet these assump-
tions. For these parameters, the Kruskal-Wallis test was performed to analyze between the four
experimental groups, followed by the Mann-Whitney test to compare between two groups
individually (Prism 5.0, GraphPad Software, CA, USA). All statistical tests were 2-tailed and
p< 0.05 was regarded as significant. Results are presented as mean ± SD (standard deviation).
Results
Induction of BD showed a uniform pattern in alterations of the MAP consistent with earlier
reports, with a mean time of BD declaration of 33.26 ± 3.45 min. The MAP of all 28 animals
was kept above 80 mmHg during the experiment (S1 Fig). Comparing the BD groups, vehicle-
treated animals received 0.91 ± 0.19 ml of HAES 10% to sustain a MAP above 80 mmHg versus
0.78 ± 0.27 ml in the T3-treated group, not reaching statistical difference (p = 0.50). The
amount of NA used in the BD groups was 1.03 ± 1.25 ml in the vehicle-treated and 0.23 ± 0.34
ml in the T3-treated group (p = 0.16, S2 Fig).
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Plasma levels of liver enzymes AST and ALT were measured as liver cell injury markers.
AST and ALT levels were significantly higher in brain-dead animals compared to sham ani-
mals (p< 0.05). Yet, T3-treatment in brain-dead as well as sham animals significantly reduced
AST and ALT levels compared to vehicle-treated animals (p< 0.05, Fig 1). A histological anal-
ysis of HE stained, paraffin-embedded slides revealed no recognizable injury pattern, conserved
cytoarchitecture and lobule organization, normal hepatocyte appearance and localization of
portal and central veins, and no necrosis in the liver of brain-dead animals, all of which were
unaffected by T3-treatment.
In order to assess the hepatic inflammatory response in brain-dead animals, inflammatory
genes interleukin IL-6, MCP-1, and IL-1β were analyzed. The relative expression of IL-6,
MCP-1, and IL-1β were all significantly increased in brain-dead animals compared to sham
animals (p< 0.001, p< 0.001, and p< 0.05 respectively). No differences were found between
T3-treated and vehicle-treated animals (Fig 2).
To evaluate possible anti-apoptotic effects, the relative expression of complementary genes
Bcl-2 and Bax, the Bax/Bcl2 ratio, and the presence of cC3 in the liver tissue were analyzed (Fig
3). The relative expression of apoptosis promotor Bax was not significantly different in brain-
dead animals compared to sham animals. However, T3 treatment significantly lowered Bax
gene expression compared to vehicle treatment in both sham and brain-dead rats (p< 0.05).
Relative expression of apoptosis inhibitor Bcl-2 was significantly decreased following BD
(p< 0.001) but did not change in T3-treated animals. The Bax/Bcl-2 ratio shows the balance
between pro-apoptotic and anti-apoptotic genes. This ratio was significantly increased in
brain-dead animals, indicating a pro-apoptotic tendency (p< 0.01). However, the Bax/Bcl-2
ratio showed no change in T3-treated, brain-dead animals compared to vehicle-treated animals
(p = 0.053). cC3 is a protein that acts downstream of Bax and Bcl-2 control and is a key player
Fig 1. T3 pre-treatment attenuated brain death-induced hepatic injury. Plasma levels of AST and ALT were analyzed following 4 h of BD in the BD
groups and 0.5 h of ventilation in the sham groups. Groups were pre-treated with either vehicle or T3. Results are presented as mean ± SD, n = 7 per group (*
p < 0.05).
doi:10.1371/journal.pone.0138749.g001
Anti-Apoptotic Effects of T3 in the Liver of Brain-Dead Rats
PLOS ONE | DOI:10.1371/journal.pone.0138749 October 5, 2015 6 / 14
in the execution phase of cellular apoptosis. The number of cC3 positive cells in the liver of
brain-dead animals was higher compared to sham animals (p< 0.05), and was significantly
reduced following T3 treatment in both sham and brain-dead animals (p< 0.01, Fig 4).
To determine whether T3 treatment also resulted in pro-mitotic effects, the relative expres-
sion of Cyclin-D and presence of Ki-67 positive cells were analyzed. Cyclin D is involved in cell
cycle progression and Ki-67 is a marker of proliferation as it is present in all proliferating cells
[38]. The number of Ki-67 positive liver cells did not change following BD or T3 treatment (Fig
5A–5E). Relative expression of Cyclin-D in liver tissue was significantly lower in brain-dead
compared to sham animals (p< 0.001), but did not change following T3 treatment (Fig 5F).
To evaluate the oxidative stress response in the liver, STAT3 and Nrf2 gene expression and
HO-1 protein levels were studied. Levels of oxidative stress marker HO-1 were significantly
Fig 2. T3 pre-treatment did not mitigate hepatic inflammation following BD.Hepatic, relative mRNA expression of inflammation-related genes IL-6, IL-
1β, and MCP-1 was analyzed by real-time PCR, following 4 h of BD in the BD groups and 0.5 h of ventilation in the sham groups. Groups were pre-treated
with either vehicle or T3. Data are presented as mean ± SD, n = 7 per group (* p < 0.05).
doi:10.1371/journal.pone.0138749.g002
Fig 3. T3 pre-treatment attenuated hepatic apoptosis. Hepatic, relative mRNA expression of pro-apoptotic gene Bax and anti-apoptotic gene Bcl-2, and
the Bax/Bcl2 mRNA ratio were analyzed by real-time PCR, following 4 h of BD in the BD groups and 0.5 h of ventilation in the sham groups. Groups were pre-
treated with either vehicle or T3. Data are presented as mean ± SD, n = 7 per group (* p < 0.05).
doi:10.1371/journal.pone.0138749.g003
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increased in the BD groups (p< 0.0001), however, this was significantly decreased in T3-
treated animals (p< 0.05, Fig 6A–6E). The relative expression of STAT3 was significantly
increased in the BD groups (p< 0.001), yet T3 treatment significantly lowered its relative
expression (p< 0.05, Fig 7A). The relative expression of Nrf2 was decreased in both (sham and
BD) groups treated with T3, but no change was observed in brain-dead compared to sham ani-
mals (Fig 7B).
Discussion
To solve the growing disparity between organ supply and demand, hormonal therapy is widely
used as a way to improve organ quality and expand the donor pool. Regarding the treatment of
brain-dead donors, there is an ongoing discussion about the effectiveness of thyroid hormone
therapy together with a shift to start treatment earlier, even before the declaration of BD. In
light of this, this present study demonstrates that T3 administration before the induction of BD
Fig 4. T3 pre-treatment attenuated brain death-induced apoptosis in the liver. Analyses performed
following 4 h of BD in the BD groups and 0.5 h of ventilation in the sham groups. (A), (B), (C), and (D) Hepatic,
cleaved Caspase-3 (cC3) immunohistochemistry staining at 20 x original magnification from (A) sham
+ vehicle, (B) sham + T3, (C) BD + vehicle and (D) BD + T3-treated rats. The sections are representative of 7
independent rats per group. Black arrows show examples of positive cells. (E) cC3 protein quantification in
the liver, shown as the number of positive cells in the liver per field at 20 x original magnification, counted
twice in a blinded fashion.
doi:10.1371/journal.pone.0138749.g004
Fig 5. T3 pre-treatment did not give rise to mitotic effects in the liver. Analyses performed following 4 h of
BD in the BD groups and 0.5 h of ventilation in the sham groups. (A), (B), (C), and (D) Immunohistochemistry
staining of cellular proliferation marker Ki-67 at 100 x original magnification in the liver from (A) sham
+ vehicle, (B) sham + T3, (C) BD + vehicle, and (D) BD + T3-treated rats. The sections are representative of 7
independent rats per group. (E) Ki-67 protein quantification in the liver, shown as the number of positive cells
in the liver per field at 20 x original magnification, counted twice in a blinded fashion. Black arrows show
examples of positive cells. (F) Hepatic, relative mRNA expression of pro-mitotic gene Cyclin-D was analyzed
by real-time PCR. Data are presented as mean ± SD, n = 7 per group (* p < 0.05).
doi:10.1371/journal.pone.0138749.g005
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decreases liver cell injury and apoptosis in brain-dead rats, suggesting liver function improves
following T3 treatment. We show that T3 therapy reduces apoptosis initially on a transcrip-
tional level, as well as during the execution phase of apoptosis in brain-dead rats, by reduction
of cC3. This is the first time that these anti-apoptotic effects of T3 pre-conditioning have been
shown in the BD setting. Interestingly, the mechanism through which T3 exerts these anti-apo-
ptotic effects remains intact in brain-dead donors and is achieved in a short time frame. Pantos
et al. also showed that administration of T3 limited apoptosis in a Langendorff-perfused heart
model in rats, when given at the time of reperfusion [39]. But, others have shown similar pre-
conditioning effects in much larger time frames [31, 32, 40]. In the BD setting, thyroid hor-
mone therapy could thus represent a valid therapeutic opportunity to improve organ quality
before donation.
Besides reducing apoptosis, T3 also has the capacity to regenerate hepatocytes directly by
inducing mitosis [32]. In our model, T3 therapy did not alter regulation of cell cycle
Fig 6. T3 pre-treatment reduced brain death-induced oxidative stress in the liver. Analyses performed
following 4 h of BD in the BD groups and 0.5 h of ventilation in the sham groups. (A), (B), (C), and (D)
Immunohistochemistry staining of cellular oxidative stress marker HO-1 at 100 x original magnification in the
liver from (A) sham + vehicle, (B) sham + T3, (C) BD + vehicle and (D) BD + T3-treated rats. The sections are
representative of 7 independent rats per group. (E) HO-1 protein quantification in the liver, counted using
Aperio Image Scope. Data are presented as total intensity per area (mm2), n = 7 per group (* p < 0.05).
doi:10.1371/journal.pone.0138749.g006
Fig 7. T3 pre-treatment reduced brain death-induced oxidative stress in the liver. Hepatic, relative mRNA expression of oxidative stress-related
markers STAT3 and Nrf2 was analyzed by real-time PCR, following 4 h of BD in the BD groups and 0.5 h of ventilation in the sham groups. Groups were pre-
treated with either vehicle or T3. Data are presented as mean ± SD, n = 7 per group (* p < 0.05).
doi:10.1371/journal.pone.0138749.g007
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progression or expression of cellular growth markers [38]. In healthy liver cells, T3 has been
shown to activate cyclin D within 2–4 h after administration [41]. Yet, in a model of partial
hepatectomy, T3 pre-treatment increased cyclin D levels and Ki-67 positive cells no earlier
than 12 h post-surgery [32]. This suggests pro-mitotic effects are not observed in our study
either due to the short therapeutic time frame or due to a differential response to T3 in the liver
following BD. In the clinical setting, the time frame from the declaration of BD until the actual
transplantation more closely resembles models that support the idea that T3 induces pro-
mitotic effects [33, 34], Further clinical research into the pro-mitotic effects of T3 needs to be
performed to elucidate this topic.
As mentioned, the available evidence shows that BD causes detrimental pathophysiological
changes in the donor. BD is characterized as a systemic inflammatory state, seen by a rise in cir-
culating cytokines levels, including IL-6, IL-10, and MCP-1. This inflammatory environment
permits an influx of inflammatory cells in the kidneys, liver and lungs, which triggers a local
inflammatory and apoptotic response. Even though apoptosis was reduced in the T3-treated
animals in our model, this was not accompanied by alterations in inflammation. Thyroid hor-
mone treatment has also been shown to improve BD-induced hemodynamic instability and
reduce the amount of vasoactive agents required to treat brain-dead donors [23]. However,
beneficial effects of T3 therapy in this model were not accompanied by improved hemodynam-
ics or reduced vasoactive support.
These results suggest that the beneficial effects of T3 pre-conditioning may not be explained
by improvements in hemodynamic or inflammatory status in the brain-dead donor. Interest-
ingly, most of the clinical trials concluding that T3 therapy as part of the BD donor manage-
ment does not confer beneficial effects, have focused on hemodynamic parameters as the
primary outcome measurement [23, 26, 42]. However, we now show that T3 benefits the liver
not hemodynamically, but functionally by reducing liver cell injury and apoptosis. Further-
more, T3 has been shown to induce a heat-production response, associated with increased oxy-
gen consumption and reactive oxygen species (ROS) generation in the liver [43, 44]. Through
this mechanism, T3 induces a transient rise in ROS production in the Küpffer cells, resulting in
the upregulation of redox-sensitive transcription factors such as STAT3 [45, 46], as well as acti-
vation of hepatic Nrf2 [47, 48]. Through induction of transient oxidative stress by means of
these pathways, T3 prepares the liver for future injury. In our model, T3-treatment significantly
lowered STAT3 and Nrf2 expression, as well as HO-1 protein levels after 4 h of BD. This sug-
gests T3 treatment successfully pre-conditioned the liver against oxidative stress induced by BD
pathophysiology. Further research into this mechanism during different time points through-
out the BD period is needed to confirm this assumption. Finally, we understand that expansion
of the time frame of the experiment is required to shed more light on long-term pre-condition-
ing effects of T3-therapy, for example by combining this model with an isolated perfused liver
or transplantation model.
In conclusion, data presented in this study show protective pre-conditioning effects of T3
therapy in the liver of brain-dead rats. These promising results were achieved in a relatively
short time frame, supporting the notion that T3 hormone therapy could be a valid therapeutic
opportunity to improve organ quality before donation. Moreover, as organ storage methods
are rapidly shifting from static cold storage to ex vivo perfusion methods, T3 therapy could
potentially be given during the organ preservation period, thereby expanding the therapeutic
time frame. Undoubtedly, more research needs to be performed to understand possible mecha-
nisms involved as well as clinical applicability. However, these results suggest a promising role
for T3 hormone therapy as part of BD donor management, with the ultimate goal to improve
transplantation outcomes.
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Supporting Information
S1 Fig. T3 treatment did not affect the blood pressure profile of rats during 4 h of brain
death. The graph represents the mean arterial pressure in mmHg, measured by intravenous
cannulation of the left femoral artery. The record started with the BD induction, considering
time “0” as the end of BD induction and the start of the BD period. The blood pressure profile
did not significantly differ between the vehicle-treated (represented by the continuous black
line) and the T3-treated group (represented by the green continuous green line) (n = 7 per
group).
(TIF)
S2 Fig. T3 treatment did not lower amounts of vasoactive agents used during 4 h of brain
death in rats. Amounts of polyhydroxyl starch (HAES) and noradrenaline (NA, 1 mg/ml)
given to brain-dead rats during the 4 h experimental procedure to maintain a MAP above 80
mmHg did not significantly differ between T3- and sham-treated animals (p = 0.50 and
p = 0.16, respectively). Results are presented as mean ± SD (n = 7 per group).
(TIF)
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